Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Delavirdine Mesylate

FDA-approved product (tablet, oral), marketed as Rescriptor.

Registered studies
27
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Delavirdine Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Non-nucleoside reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AG02

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

27registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Delavirdine Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Delavirdine Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients

    NCT00001094

    Registered record
    Registry ID
    NCT00001094
    Conditions
    HIV Infections
    Interventions
    Lamivudine/Zidovudine; Nelfinavir mesylate; Saquinavir; Delavirdine mesylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionLamivudine/Zidovudine; Nelfinavir mesylate; Saquinavir; Delavirdine mesylate
    PhasePhase 2
    Registry statusWithdrawn

  • A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3

    NCT00002123

    Registered record
    Registry ID
    NCT00002123
    Conditions
    HIV Infections
    Interventions
    Delavirdine mesylate; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionDelavirdine mesylate; Didanosine
    PhasePhase 3
    Registry statusCompleted

  • A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3

    NCT00002124

    Registered record
    Registry ID
    NCT00002124
    Conditions
    HIV Infections
    Interventions
    Delavirdine mesylate; Lamivudine; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    1,250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionDelavirdine mesylate; Lamivudine; Zidovudine
    PhasePhase 3
    Registry statusCompleted

  • A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients

    NCT00002178

    Registered record
    Registry ID
    NCT00002178
    Conditions
    HIV Infections
    Interventions
    Ritonavir; Nelfinavir mesylate; Saquinavir; Delavirdine mesylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    375

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionRitonavir; Nelfinavir mesylate; Saquinavir; Delavirdine mesylate
    PhasePhase 3
    Registry statusCompleted

  • A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies

    NCT00002210

    Registered record
    Registry ID
    NCT00002210
    Conditions
    HIV Infections
    Interventions
    Delavirdine mesylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionDelavirdine mesylate
    PhasePhase 2
    Registry statusCompleted

  • Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients

    NCT00002211

    Registered record
    Registry ID
    NCT00002211
    Conditions
    HIV Infections
    Interventions
    Nelfinavir mesylate; Delavirdine mesylate; Stavudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionNelfinavir mesylate; Delavirdine mesylate; Stavudine; Didanosine
    PhaseNot applicable
    Registry statusCompleted

  • A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients

    NCT00002236

    Registered record
    Registry ID
    NCT00002236
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Delavirdine mesylate; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Delavirdine mesylate; Zidovudine
    PhaseNot applicable
    Registry statusCompleted

  • The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine

    NCT00002312

    Registered record
    Registry ID
    NCT00002312
    Conditions
    HIV Infections
    Interventions
    Delavirdine mesylate; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionDelavirdine mesylate; Zidovudine
    PhaseNot applicable
    Registry statusCompleted

  • A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients

    NCT00002378

    Registered record
    Registry ID
    NCT00002378
    Conditions
    HIV Infections
    Interventions
    Ritonavir; Nelfinavir mesylate; Saquinavir; Delavirdine mesylate; Lamivudine; Stavudine; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    825

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionRitonavir; Nelfinavir mesylate; Saquinavir; Delavirdine mesylate +3 more
    PhasePhase 3
    Registry statusCompleted

  • A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients

    NCT00002400

    Registered record
    Registry ID
    NCT00002400
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Delavirdine mesylate; Lamivudine; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Delavirdine mesylate; Lamivudine; Zidovudine
    PhaseNot applicable
    Registry statusCompleted

  • A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients

    NCT00002401

    Registered record
    Registry ID
    NCT00002401
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Delavirdine mesylate; Lamivudine; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Delavirdine mesylate; Lamivudine; Zidovudine
    PhaseNot applicable
    Registry statusCompleted

  • The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors

    NCT00002420

    Registered record
    Registry ID
    NCT00002420
    Conditions
    HIV Infections
    Interventions
    Emivirine; Hydroxyurea; Delavirdine mesylate; Stavudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionEmivirine; Hydroxyurea; Delavirdine mesylate; Stavudine +1 more
    PhasePhase 2
    Registry statusTerminated